当前位置:
X-MOL 学术
›
Arthritis Rheumatol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib
Arthritis & Rheumatology ( IF 11.4 ) Pub Date : 2024-10-21 , DOI: 10.1002/art.43042 Runa Kuley, Bhargavi Duvvuri, Sabeeha Hasnain, Ernst R. Dow, Alisa E. Koch, Richard E. Higgs, Venkatesh Krishnan, Christian Lood
Arthritis & Rheumatology ( IF 11.4 ) Pub Date : 2024-10-21 , DOI: 10.1002/art.43042 Runa Kuley, Bhargavi Duvvuri, Sabeeha Hasnain, Ernst R. Dow, Alisa E. Koch, Richard E. Higgs, Venkatesh Krishnan, Christian Lood
Neutrophils play an important role in regulating immune and inflammatory responses in patients with rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce neutrophil activation and whether a neutrophil activation score could predict treatment response.
中文翻译:
中性粒细胞活化标志物和类风湿关节炎治疗对 JAK1/2 抑制剂巴瑞克替尼的反应
中性粒细胞在调节类风湿性关节炎 (RA) 患者的免疫和炎症反应中起着重要作用。我们评估了 JAK1/JAK2 抑制剂巴瑞替尼是否可以减少中性粒细胞活化,以及中性粒细胞活化评分是否可以预测治疗反应。
更新日期:2024-10-21
中文翻译:
中性粒细胞活化标志物和类风湿关节炎治疗对 JAK1/2 抑制剂巴瑞克替尼的反应
中性粒细胞在调节类风湿性关节炎 (RA) 患者的免疫和炎症反应中起着重要作用。我们评估了 JAK1/JAK2 抑制剂巴瑞替尼是否可以减少中性粒细胞活化,以及中性粒细胞活化评分是否可以预测治疗反应。